Overview

A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy

Status:
RECRUITING

Trial end date:
2031-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to the 6-month Venous Thromboembolism (VTE)-free rate in participants with advanced germ cell cancer at high risk of VTE who are receiving standard of care cisplatin-based chemotherapy and low-dose acetylsalicylic acid (ASA) and compare to relevant historical controls

Phase:

PHASE2

Details

Lead Sponsor:

Wake Forest University Health Sciences

Collaborator:

Atrium Health Wake Forest Baptist

Treatments:

Aspirin